About GrandOmics
GrandOmics is a Healthcare company based in Haidian (China) founded in 2011. Bioinformatics and gene sequencing services for research are provided. It operates on a Professional Services, Data-as-a-Service, and HealthTech model. GrandOmics has raised $29.6 million across 2 funding rounds from investors including Marathon Venture Partners, Matrix Partners China and Zero2IPO Ventures. Its chief executive, as recorded, is Depeng Wang. GrandOmics offers products and services including BAC-long Ultra-Long Sequencing Kit, T2T Pan-Genome Breeding, Third-Generation Metagenomics, Single-Cell Full-Length Transcriptomics, and GrandBox Integrated Solution. Its focus areas include Biotechnology, Genomics, Technology and Bioinformatics. Its legal entity is Beijing GrandOmics Biotechnology Co., Ltd.
Company details
GrandOmics is established as a leader in third-generation sequencing technology, focusing on technical development and application expansion. Services are provided across four main modules: scientific services, medical diagnostics, bioinformatics, and advanced manufacturing. Operations are supported by facilities in Beijing and Wuhan, spanning over 5,000 square meters. Advanced platforms like ONT PromethION 48 and PacBio Sequel II are utilized for cutting-edge research. Solutions are offered for genomics, transcriptomics, and microbiomics, catering to both research and medical sectors. Innovation is driven through proprietary software and databases for sequencing analysis. Recognition is received through awards and consistent rankings in the Nature Index.
- Headquarters Haidian, China
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website grandomics.com
- Social LinkedIn X
- Legal Name Beijing Grandomics Biotechnology Co., Ltd.
- Total Equity Funding$29.6M (USD)
in 2 rounds
- Latest Funding Round$15.1M (USD), Series B
Jul 2018
- InvestorsMarathon Venture Partners
& 3 more
Products & Services of GrandOmics
GrandOmics offers a comprehensive portfolio of products and services, including BAC-long Ultra-Long Sequencing Kit, T2T Pan-Genome Breeding, Third-Generation Metagenomics, Single-Cell Full-Length Transcriptomics, and GrandBox Integrated Solution.
Ultra-long sequencing fragments are produced for genomic analysis.
Complete genomes are analyzed for accelerated breeding applications.
Diversity classification is enhanced through new species discovery.
Isoform differences are studied in single-cell transcriptomic research.
Long-read sequencing data is analyzed with high-performance servers.
Funding Insights of GrandOmics
GrandOmics has successfully raised a total of $29.6M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $15.1 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29.6M
- Total Rounds 2
- Last Round Series B — $15.1M
- First Round $14.5M
(Dec 2016)
- Investors Count 4
All 2 funding rounds of GrandOmics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2018 | $15.1M | Series B | – | Marathon Venture Partners | |
| Dec 2016 | $14.5M | Series A | – | – |
4 investors in total: 4 institutional.
Investors in GrandOmics
GrandOmics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Marathon Venture Partners, Matrix Partners China and Zero2IPO Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| marathonvp.com | ||||
Multiple sectors are invested in by this venture capital firm. | matrixpartners.com.cn | Chaoyang, China | ||
| zero2ipovc.com | ||||
A leading private equity firm supporting high-growth enterprises in Asia. | saifpartners.com.cn | Chaoyang, China |
Investor details for GrandOmics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GrandOmics
1 people are tracked at GrandOmics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Depeng Wang | CEO | Leadership |
Complete people profiles for GrandOmics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GrandOmics
3 dated milestones of GrandOmics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded GrandOmics is founded.
- Funding First funding round of $14.5M.
- Funding Latest funding round, Series B, of $15.1M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GrandOmics
GrandOmics was founded in 2011 and raised its 1st funding round 5 years after it was founded.
GrandOmics is headquartered in Haidian, China. It is registered at Haidian, Beijing, China.
Depeng Wang is the CEO of GrandOmics, as recorded in our data.
GrandOmics is a funded company, having raised a total of $29.6M across 2 funding rounds to date. The company's 1st funding round was a Series A of $14.5M, raised on Dec 2016.
GrandOmics is established as a leader in third-generation sequencing technology, focusing on technical development and application expansion. Services are provided across four main modules: scientific services, medical diagnostics, bioinformatics, and advanced manufacturing. Operations are supported by facilities in Beijing and Wuhan, spanning over 5,000 square meters. Advanced platforms like ONT PromethION 48 and PacBio Sequel II are utilized for cutting-edge research. Solutions are offered for genomics, transcriptomics, and microbiomics, catering to both research and medical sectors. Innovation is driven through proprietary software and databases for sequencing analysis. Recognition is received through awards and consistent rankings in the Nature Index.
GrandOmics offers BAC-long Ultra-Long Sequencing Kit, T2T Pan-Genome Breeding, Third-Generation Metagenomics, Single-Cell Full-Length Transcriptomics, and GrandBox Integrated Solution.
GrandOmics has 4 investors. Key investors include Marathon Venture Partners, Matrix Partners China, Zero2IPO Ventures, and SAIF Partners China.
GrandOmics operates through Beijing Grandomics Biotechnology Co., Ltd..